Xeris Biopharma (NASDAQ:XERS) Shares Up 5.4% – What’s Next?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)’s share price rose 5.4% during mid-day trading on Thursday . The company traded as high as $5.64 and last traded at $5.5850. Approximately 765,476 shares traded hands during trading, a decline of 62% from the average daily volume of 2,008,487 shares. The stock had previously closed at $5.30.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. Barclays started coverage on shares of Xeris Biopharma in a research note on Monday, December 8th. They issued an “overweight” rating and a $9.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research report on Monday, March 2nd. Finally, Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Xeris Biopharma Trading Up 5.0%

The business has a fifty day moving average of $6.57 and a 200-day moving average of $7.38. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.57 and a current ratio of 2.19. The company has a market capitalization of $959.57 million, a P/E ratio of -561.94 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. The firm had revenue of $85.81 million for the quarter, compared to the consensus estimate of $86.00 million. Analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, insider John Patrick Shannon, Jr. sold 24,907 shares of Xeris Biopharma stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $7.08, for a total transaction of $176,341.56. Following the completion of the transaction, the insider owned 2,705,346 shares in the company, valued at approximately $19,153,849.68. The trade was a 0.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Beth Hecht sold 16,667 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $7.43, for a total value of $123,835.81. Following the completion of the sale, the insider directly owned 1,308,103 shares of the company’s stock, valued at approximately $9,719,205.29. This trade represents a 1.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 89,908 shares of company stock valued at $648,515. 6.47% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xeris Biopharma

Several large investors have recently bought and sold shares of XERS. Kestra Advisory Services LLC purchased a new position in Xeris Biopharma during the 4th quarter worth $25,000. AlphaQuest LLC bought a new position in shares of Xeris Biopharma during the third quarter valued at about $35,000. Caitong International Asset Management Co. Ltd boosted its holdings in Xeris Biopharma by 9,276.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after purchasing an additional 7,421 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after purchasing an additional 1,820 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after buying an additional 5,000 shares during the last quarter. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.